NVCT Nuvectis Pharma, Inc. - Common Stock
$11,14
Fiyat · May 22, 2026
Temel veriler itibarıyla May 5, 2026
52 Haftlık Aralık
$6–$13
72% of range
Analist Derecelendirmesi
BUY
11 analysts
Fiyat Hedefi
$17
+51% upside
P/E (TTM)
-5.7
ROE
-149.9%
Net Kâr Marjı
—
NVCT Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$11.14
Piyasa Değeri
$194M
P/E (TTM)
-5.7
EPS (TTM)
$-1.32
Gelir (TTM)
—
Temettü Verimi
—
ROE
-149.9%
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$6 – $13
NVCT Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
—
Hisse Başına Kâr
$-1.32
2021-12-31
→
2025-12-31
Serbest Nakit Akışı
—
Marjlar
—
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
NVCT
Akran Ortalaması
P/E (TTM)
-5.7
9.4
P/B (F/D)
10.5
1.8
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
NVCT
Akran Ortalaması
ROA
-105.1%
-30.4%
ROE
-149.9%
-54.4%
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
NVCT
Akran Ortalaması
Current Ratio (Cari Oran)
2.4
3.8
Quick Ratio (Cari Oran)
2.4
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
NVCT
Akran Ortalaması
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
NVCT
Akran Ortalaması
NVCT Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
11 analist
- Güçlü Al 2 18,2%
- Al 8 72,7%
- Tut 1 9,1%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
5 analist · 2026-05-21
Medyan
$18.00
Ortalama
$16.80
Şimdi
$11.14
Düşük
$10.00
Yüksek
$20.00
Medyan hedef
$18.00
+61,6%
Ortalama hedef
$16.80
+50,8%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-0.02%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 31 Mart 2026 | $-0.26 | $-0.32 | 0.06% |
| 31 Aralık 2025 | $-0.31 | $-0.30 | -0.01% |
| 30 Eylül 2025 | $-0.33 | $-0.25 | -0.08% |
| 30 Haziran 2025 | $-0.30 | $-0.26 | -0.04% |
| 31 Mart 2025 | $-0.27 | $-0.26 | -0.01% |
Eş Karşılaştırması Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| NVCT | $194M | -5.7 | — | — | -149.9% | — |
| ELDN | $114M | -2.9 | — | — | -69.4% | — |
| SABS | — | — | — | — | — | — |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | — |
| TARA | $286M | -4.0 | — | — | -33.7% | — |
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
| ALXO | $61M | -0.6 | — | — | -225.0% | — |
| FATE | $113M | -0.9 | -51.2% | -2051.1% | -58.2% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 9
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| R&D Expense | $18M | $13M | $15M | $13M | $10M | |
| SG&A Expense | $9M | $7M | $8M | $6M | $3M | |
| Operating Income | $-28M | $-20M | $-23M | $-19M | $-13M | |
| Net Income | $-26M | $-19M | $-22M | $-19M | $-13M | |
| EPS (Basic) | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 | |
| EPS (Diluted) | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 | |
| Shares (Basic) | 21,812,716 | 17,113,169 | 15,556,655 | 12,657,651 | 4,268,285 | |
| Shares (Diluted) | 21,812,716 | 17,113,169 | 15,556,655 | 12,657,651 | 4,268,285 | |
| EBITDA | $-28M | $-20M | $-23M | · | · |
Bilanço 13
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $32M | $19M | $19M | $20M | $6M | |
| Other Current Assets | $75.0K | $74.0K | $59.0K | $412.0K | $91.0K | |
| Current Assets | $32M | $19M | $19M | $20M | $6M | |
| Total Assets | $32M | $19M | $19M | $20M | $7M | |
| Accounts Payable | $6M | $2M | $3M | $3M | $1M | |
| Accrued Liabilities | $115.0K | $840.0K | $415.0K | $445.0K | $395.0K | |
| Current Liabilities | $13M | $9M | $7M | $6M | $2M | |
| Total Liabilities | $13M | $9M | $7M | $6M | $2M | |
| Paid-in Capital | $118M | $83M | $66M | $46M | $2M | |
| Retained Earnings | $-100M | $-73M | $-54M | $-32M | $-13M | |
| Stockholders' Equity | $18M | $10M | $12M | $14M | $-11M | |
| Liabilities + Equity | $32M | $19M | $19M | $20M | $7M | |
| Shares Outstanding | 25,676,798 | 19,495,683 | 17,418,886 | 15,190,720 | 4,505,514 |
Nakit Akışı 6
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $5M | $5M | $2M | $2M | |
| Operating Cash Flow | $-16M | $-12M | $-16M | $-14M | $-10M | |
| Investing Cash Flow | · | · | $0 | $0 | · | |
| Stock Issued | · | $12M | $5M | · | · | |
| Net Stock Activity | · | $12M | $5M | · | · | |
| Financing Cash Flow | $29M | $12M | $15M | $28M | $15M |
Kârlılık 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| ROA | -105.1% | -100.6% | -112.5% | · | · | |
| ROE | -149.9% | -183.5% | -154.1% | · | · |
Likidite ve Solventlik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 2.1 | 2.7 | · | · | |
| Quick Ratio | 2.4 | 2.1 | 2.7 | · | · |
Değerleme (TTM) 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Net Income TTM | $-26M | $-19M | $-22M | $-19M | $-13M | |
| Market Cap | $194M | $105M | $145M | · | · | |
| P/E | -5.7 | -4.9 | -5.8 | -5.0 | · | |
| P/B | 10.5 | 10.9 | 11.9 | · | · | |
| P / Tangible Book | 10.5 | 10.9 | 11.9 | 7.7 | · | |
| P / Cash Flow | -12.1 | -8.6 | -9.1 | · | · | |
| Earnings Yield | -17.5% | -20.5% | -17.2% | -20.1% | · |
Gelir Tablosu 9
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $4M | $5M | $6M | $4M | $4M | $4M | $3M | $3M | $3M | $4M | $4M | $4M | $2M | $4M | $5M | $3M | |
| SG&A Expense | $2M | $3M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | |
| Operating Income | $-6M | $-8M | $-8M | $-7M | $-6M | $-6M | $-4M | $-5M | $-4M | $-7M | $-6M | $-6M | $-4M | $-7M | $-6M | $-4M | |
| Net Income | $-6M | $-7M | $-7M | $-6M | $-5M | $-6M | $-4M | $-4M | $-4M | $-7M | $-6M | $-6M | $-4M | $-7M | $-6M | $-4M | |
| EPS (Basic) | $-0.26 | $-0.31 | $-0.44 | $-0.30 | $-0.27 | $-0.36 | $-0.24 | $-0.26 | $-0.25 | $-0.41 | $-0.37 | $-0.38 | $-0.27 | $-0.49 | $-0.42 | $-0.28 | |
| EPS (Diluted) | $-0.26 | $-0.31 | $-0.44 | $-0.30 | $-0.27 | $-0.36 | $-0.24 | $-0.26 | $-0.25 | $-0.41 | $-0.37 | $-0.38 | $-0.27 | $-0.49 | $-0.42 | $-0.28 | |
| Shares (Basic) | 23,414,475 | -42,210,116 | 22,719,057 | 21,366,268 | 19,937,507 | -33,577,295 | 17,230,559 | 16,900,570 | 16,559,335 | -30,450,075 | 16,104,446 | 15,178,035 | 14,724,249 | -23,269,553 | 14,050,271 | 12,717,794 | |
| Shares (Diluted) | 23,414,475 | -42,210,116 | 22,719,057 | 21,366,268 | 19,937,507 | -33,577,295 | 17,230,559 | 16,900,570 | 16,559,335 | -30,450,075 | 16,104,446 | 15,178,035 | 14,724,249 | -23,269,553 | 14,050,271 | 12,717,794 | |
| EBITDA | $-6M | · | $-8M | $-7M | $-6M | · | $-4M | $-5M | $-4M | · | $-6M | $-6M | $-4M | · | $-6M | $-4M |
Bilanço 13
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25M | $32M | $35M | $27M | $30M | $19M | $17M | $18M | $19M | $19M | $22M | $25M | $15M | $20M | $24M | $14M | |
| Other Current Assets | $268.0K | $75.0K | $145.0K | $214.0K | $284.0K | $74.0K | $138.0K | $182.0K | $250.0K | $59.0K | $203.0K | $341.0K | $740.0K | $412.0K | $1M | $666.0K | |
| Current Assets | $25M | $32M | $36M | $27M | $30M | $19M | $17M | $18M | $20M | $19M | $22M | $25M | $16M | $20M | $25M | $14M | |
| Total Assets | $25M | $32M | $36M | $27M | $30M | $19M | $17M | $18M | $20M | $19M | $22M | $25M | $16M | $20M | $25M | $14M | |
| Accounts Payable | $5M | $6M | $6M | $5M | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $2M | $2M | $3M | $2M | $1M | |
| Accrued Liabilities | $36.0K | $115.0K | $65.0K | $2.0K | $865.0K | $840.0K | $282.0K | $310.0K | $486.0K | $415.0K | $158.0K | $571.0K | $156.0K | $445.0K | $738.0K | $790.0K | |
| Current Liabilities | $11M | $13M | $12M | $10M | $9M | $9M | $6M | $6M | $6M | $7M | $6M | $5M | $4M | $6M | $4M | $3M | |
| Total Liabilities | $11M | $13M | $12M | $10M | $9M | $9M | $6M | $6M | $6M | $7M | $6M | $5M | $4M | $6M | $4M | $3M | |
| Paid-in Capital | $120M | $118M | $116M | $102M | $100M | $83M | $78M | $75M | $72M | $66M | $64M | $62M | $48M | $46M | $46M | $31M | |
| Retained Earnings | $-106M | $-100M | $-92M | $-85M | $-79M | $-73M | $-67M | $-63M | $-58M | $-54M | $-48M | $-42M | $-36M | $-32M | $-25M | $-19M | |
| Stockholders' Equity | $14M | $18M | $24M | $17M | $21M | $10M | $11M | $13M | $14M | $12M | $17M | $20M | $12M | $14M | $20M | $12M | |
| Liabilities + Equity | $25M | $32M | $36M | $27M | $30M | $19M | $17M | $18M | $20M | $19M | $22M | $25M | $16M | $20M | $25M | $14M | |
| Shares Outstanding | 26,525,533 | 25,676,798 | 25,639,896 | 23,877,587 | 23,634,586 | 19,495,683 | 18,985,324 | 18,748,751 | 18,356,060 | 17,418,886 | 17,309,911 | 17,221,113 | · | 15,190,720 | 14,642,483 | 12,717,794 |
Nakit Akışı 6
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $1M | $1M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $950.0K | $1M | $482.0K | $559.0K | $510.0K | |
| Operating Cash Flow | $-7M | $-4M | $-4M | $-3M | $-4M | $-2M | $-2M | $-3M | $-4M | $-4M | $-3M | $-4M | $-5M | $-4M | $-4M | $-3M | |
| Investing Cash Flow | $0 | · | · | · | $0 | · | · | · | $0 | · | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | $2M | $2M | $5M | $901.0K | $1M | · | · | · | · | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $5M | · | · | · | · | · | · | · | |
| Financing Cash Flow | $7.0K | $166.0K | $13M | $296.0K | $16M | $4M | $1M | $2M | $5M | $917.0K | $703.0K | $13M | $252.0K | $-131.0K | $14M | $-578.0K |
Kârlılık 2
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -21.8% | · | -28.2% | -28.0% | -21.4% | · | -21.0% | -20.5% | -23.2% | · | -25.0% | -29.1% | -23.9% | · | -47.3% | -50.1% | |
| ROE | -34.4% | · | -42.6% | -43.1% | -30.5% | · | -30.0% | -27.0% | -31.7% | · | -31.7% | -35.9% | -30.2% | · | -57.7% | -62.1% |
Likidite ve Solventlik 2
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | · | 3.1 | 2.7 | 3.3 | · | 2.7 | 3.2 | 3.5 | · | 4.0 | 5.4 | 4.1 | · | 5.5 | 5.2 | |
| Quick Ratio | 2.2 | · | 3.1 | 2.6 | 3.2 | · | 2.7 | 3.1 | 3.4 | · | 4.0 | 5.3 | 3.9 | · | 5.3 | 5.0 |
Değerleme (TTM) 7
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-25M | · | $-23M | $-20M | $-18M | · | $-19M | $-20M | $-20M | · | $-22M | $-19M | $-16M | · | $-17M | $-17M | |
| Market Cap | $205M | · | $154M | $178M | $231M | · | $119M | $119M | $151M | · | $223M | $275M | · | · | $104M | $142M | |
| P/E | -6.1 | · | -4.8 | -7.0 | -9.6 | · | -5.6 | -5.0 | -6.5 | · | -9.0 | -11.8 | -10.2 | · | -3.4 | -3.6 | |
| P/B | 14.4 | · | 6.4 | 10.6 | 11.0 | · | 10.9 | 9.5 | 10.7 | · | 13.4 | 13.5 | · | · | 5.1 | 12.4 | |
| P / Tangible Book | 14.4 | · | 6.4 | 10.6 | 11.0 | · | 10.9 | 9.5 | 10.7 | · | 13.4 | 13.5 | · | · | 5.1 | 12.4 | |
| P / Cash Flow | -31.5 | · | · | · | -55.3 | · | · | · | -34.5 | · | · | · | · | · | · | · | |
| Earnings Yield | -16.4% | · | -20.8% | -14.3% | -10.4% | · | -17.8% | -19.9% | -15.5% | · | -11.2% | -8.5% | -9.8% | · | -29.1% | -27.4% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Net Gelir | $-26M | $-19M | $-22M | $-19M | $-13M |
| Seyreltilmiş Hisse Başı Kâr | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | 2.4 | 2.1 | 2.7 | — | — |
| Cari Oran | 2.4 | 2.1 | 2.7 | — | — |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.